| Pharmaceutical Information |
| Drug Name |
Dornase alfa |
| Drug ID |
BADD_D00711 |
| Description |
Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. |
| Indications and Usage |
Used as adjunct therapy in the treatment of cystic fibrosis. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB00003
|
| KEGG ID |
D03896
|
| MeSH ID |
C568813
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0JE4D
|
| NDC Product Code |
50242-099; 50242-100; 69438-0012 |
| UNII |
953A26OA1Y
|
| Synonyms |
dornase alfa | dornase alpha | rhDNase | recombinant human DNase | recombinant human deoxyribonuclease I | Pulmozyme |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
143831-71-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
